Comparison of the cytotoxicity of two nitroheterociclic drugs (NHCD) towards transformed and non-transformed cells

Pharmacological Research

Volumn 48, Issue 4, 2003, Pages 369-375

  Rossa, Marcelo M ^a   Rocha e Silva, Thomaz A A ^a   Terruggi, Cristina H B ^a   Tedesco, Antonio C ^b   Selistre de Araujo, Heloisa S ^a   Borissevich, Iouri E ^b   Degterev, Igor A ^a,c  

^a FEDERAL UNIVERSITY OF SÃO CARLOS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c EMANUEL INSTITUTE OF BIOCHEMICAL PHYSICS   (Russian Federation)

Author keywords

Cytotoxicity; Erythroleukaemia K562; Fibroblasts NIH3T3; Lympholeukaemia P388; Nitroheterocyclic drug

Indexed keywords

2 (5' NITRO 2' FURANYL)ETHENYL 4 [N [4 (N,N DIETHYLAMINO) 1' METHYLBUTYL]CARBAMOYL]QUINOLINE; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; HETEROCYCLIC COMPOUND; NITRACRINE; NITRO DERIVATIVE; QUINIFURYL; UNCLASSIFIED DRUG; QUINOLINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CELL DEATH; CELL IMMORTALIZATION; CELL TRANSFORMATION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOPATHOGENIC EFFECT; DRUG TRANSFORMATION; DRUG UPTAKE; ERYTHROLEUKEMIA CELL; HUMAN; HUMAN CELL; LC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE CULTURE; ANIMAL; CELL CULTURE; CELL HYPOXIA; CELL LINE; CELL STRAIN 3T3; CELL STRAIN K 562; COMPARATIVE STUDY; DRUG EFFECT; LEUKEMIA P 388; METABOLISM;

ANIMALS; CELL HYPOXIA; CELL LINE; CELL LINE, TRANSFORMED; HUMANS; K562 CELLS; LEUKEMIA P388; MICE; NIH 3T3 CELLS; NITRACRINE; QUINOLINES; TUMOR CELLS, CULTURED;

EID: 0041666495     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(03)00183-X     Document Type: Article

References (17)

1. Verovskiy V.N., Degterev I.A., Sukhova N.M., Buzukov A.A., Leonova E.Yu., Tatarskaya N.K. Interrelation between structure, microssomal metabolising activation, mouse toxicity, cytotoxicity and antitumour activity of heterocyclic- and nitroheterocyclic compounds. In vitro and in vivo study. Pharma. Chem. J. 24:1990;20-24.
2. Wilson W.R., Denny W.A., Stewart G.M., Fenn A., Probert J.C. Reductive metabolism and hypoxia-selective toxicity of nitracrine. Int. J. Radiat. Oncol. Biol. Phys. 12:1986;1235-1238.
3. Gniazdowski M., Szmigiero L. Nitracrine and its congeners - an overview. Gen. Pharmacol. 26:1995;473-481.
4. Gorlewska K., Mazerska Z., Sowin'ski P., Konopa J. Products of metabolic activation of the antitumor drug Ledakrin (Nitracrine) in Vitro. Chem. Res. Toxicol. 14:2001;1-10.
5. Voronina S.S., Tatarskaia N.K., Degterev I.A., Serebriany A.M., Pelevina I.I. Radiosensitising activity and metabolism of nitrofuran derivatives. Preparation M-106. Radiobiology (Moscow). 25:1985;748-751.
6. Smirnov S.M., Zhurav M.A., Tatarskaya N.K., Borisevich Y.E., Degterev I.A. Phototransformation of quinifur nitroanion radical formation. Chemical Physics (Moscow). 8:1989;17-23.
7. Tatarskaya N.K., Zhurav M.A., Smirnov S.M., Degterev I.A., Tarasov V.F., Borisevich Y.E.et al. Effect of compound and oxygen concentration on primary processes of quinifur phototransformation. Proc. Acad. Sci. USSR, Chem. N 5:1989;804-809.
8. Josephy PD, Mason RP. Nitroimidazoles. In: Anders MW, editor. Bioactivation of foreign compounds. New York: Academic Press; 1985. p. 161-222.
9. Degterev I.A., Buzukov A.A., Sharf V.G., Popov K.N., Serebrianiy A.M., Zaikov G.E. Comparative study of in vitro ledakrine metabolism in microssomes of EAC-cells and mouse liver. Pharma. Chem. J. 20:1986;412-417.
10. Klein E., Ben-Bassat H., Neumann H., Ralph P., Zeuthen J., Polliac A.et al. Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int. J. Cancer. 18:1976;421-431.
11. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1983;55-63.
12. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D.et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. JNCI. 83:1991;757-766.
13. WHO Chronicle, vol. 30 (Suppl. 3). Geneva: World Health Organization; 1976. p. 11.
14. Gniazdowski M, Filipski J, Chorazy M. Nitracrine. In: Hahn FE, editor. Antibiotics V/2. Berlin: Springer; 1979. p. 275-97.
15. Wilson W.R., Denny W.A., Twigden S.J., Baguley B.C., Probert J.C. Selective toxicity of nitracrine to hypoxic mammalian cells. Br. J. Cancer. 49:1984;215-223.
16. Blatun L.A., Svetukhin A.M., Pal'tsyn A.A., Liapunov N.A., Agafonov V.A. Clinic-laboratory effectiveness of modern ointments with a polyethylene glycol base in the treatment of purulent wounds. Antibiot. Khimioterapia. 44:1999;25-31.
17. Degterev I.A., Buzukov A.A., Tatarskaya N.K., Leonova E.Yu, Sukhova N.M. Metabolism of heterocyclic compounds in mouse liver microsomes. Pharma. Chem. J. 24:1990;9-16.